<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03493568</url>
  </required_header>
  <id_info>
    <org_study_id>Be-OnE Study</org_study_id>
    <nct_id>NCT03493568</nct_id>
  </id_info>
  <brief_title>Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE)</brief_title>
  <acronym>Be-OnE</acronym>
  <official_title>Open Label, Randomized (1:1) Clinical Trial to Evaluate Switching From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE Study).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ospedale San Raffaele</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research hypothesis:

      Switching from dual regimens based on dolutegravir plus a RTI to a single tablet regimen of
      elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), lowers the exposure
      to Residual Viremia (and hence the risk of viral rebound), without increasing treatment
      toxicity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design Randomized, single-center, open-label, 96-week superiority study. Patients with
      HIV-RNA &lt;50 copies/mL while receiving DTG plus one RTI will be randomized 1:1 to continue the
      ongoing treatment or to switch to E/C/F/TAF.

      Randomization list will be a computer-generated list (with equal block sizes) and will be
      incorporated within an electronic clinical report form (eCRF).

      Patients will be evaluated at screening, baseline, week 4, 8, 16, 24, 32, 40, 48, 60, 72, 84,
      96 or premature discontinuation.

      At each visit the following evaluations will be performed:

        1. clinical assessment.

        2. routine laboratory tests (hematological tests and clinical chemistry). Additional blood
           samples will be collected at specified visits for storage and further determinations
           (e.g. RV by a single-copy assay).

      During follow-up, at different timepoints, patients will additionally undergo HIV-DNA
      quantification in PBMCs (BL, 48 and 96 weeks) and quality of life (QOL) and adherence
      assessement (BL, 48 and 96 weeks).

      Viral load will be assessed by Abbott Real time PCR (Abbott RealTime HIV-1) Residual viremia
      (RV) will be defined as any detectable HIV-RNA value below 50 copies/mL Virologic failure
      will be defined as a confirmed rebound in plasma HIV-RNA levels ≥ 50 copies/mL

      Subjects who meet a protocol-defined virologic failure during follow-up will be discontinued
      from the study.

      At virologic failure subjects will perform genotypic HIV resistance testing and a
      determination in plasma of elvitegravir or DTG Cthrough.

      HIV-DNA will be extracted from 1x106 peripheral blood mononuclear cells (PBMCs) by using
      Qiagen DNA extraction kit and quantified by Real Time PCR (ABI Prism 7900).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 20, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Treatments
Genvoya 150Mg-150Mg-200Mg-10Mg Tablet ( 1 pill every 24 hours)
Dolutegravir 50 mg (1 pill every 24 hours) plus one Reverse Trascriptase Inhibitor (at label dose)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Residual Viremia</measure>
    <time_frame>48 weeks</time_frame>
    <description>To investigate RV through 48 weeks in virologically suppressed patients randomized to continue treatment with DTG plus a single RTI or to switch to E/C/F/TAF.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>virological rebound</measure>
    <time_frame>48 weeks</time_frame>
    <description>To investigate the occurrence of virological rebound above 50 HIV-RNA copies/mL;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>viral reservoir</measure>
    <time_frame>48 weeks</time_frame>
    <description>To investigate changes in viral reservoir (HIV-DNA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL</measure>
    <time_frame>48 weeks</time_frame>
    <description>To investigate changes in the quality of life (administration of questionnaire ISSQoL uses five- point Likert scales 1 never 2 rarely 3 sometimes 4 often 5 always)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>48 weeks</time_frame>
    <description>To investigate changes in adherence (administration of questionnaire uses scale ranges from 0 to 100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological failure</measure>
    <time_frame>96 weeks</time_frame>
    <description>proportion of patient in virological rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>viral reservoir</measure>
    <time_frame>96 weeks</time_frame>
    <description>change in viral reservoir (HIV-DNA extracted from peripheral blood mononuclear cells by using Qiagen DNA extraction kit and quantified by Real Time PCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL</measure>
    <time_frame>96 weeks</time_frame>
    <description>To investigate changes in the quality of life (administration of questionnaire To investigate changes in the quality of life (administration of questionnaire ISSQoL uses five- point Likert scales 1 never 2 rarely 3 sometimes 4 often 5 always))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence.</measure>
    <time_frame>96 weeks</time_frame>
    <description>To investigate changes in adherence (administration of questionnaire uses scale ranges from 0 to 100 )</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Genvoya 150Mg-150Mg-200Mg-10Mg Table</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>switch to the treatment Genvoya 150Mg-150Mg-200Mg-10Mg Table (1 pill every 24 hour)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dolutegravir 50 mg plus one RTI (at label dose)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuing Dolutegravir 50 mg (1 pill every 24 hours) plus one RTI (at label dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Genvoya 150Mg-150Mg-200Mg-10Mg Tablet</intervention_name>
    <description>switch to Genvoya 150Mg-150Mg-200Mg-10Mg Tablet in patients virologically suppressed HIV-1 infected patients.</description>
    <arm_group_label>Genvoya 150Mg-150Mg-200Mg-10Mg Table</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir 50 mg plus one RTI</intervention_name>
    <description>Continuing Dolutegravir 50 mg (1 pill every 24 hours) plus one RTI (at label dose)</description>
    <arm_group_label>Dolutegravir 50 mg plus one RTI (at label dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;18 years

          2. Willing and able to provide informed consent

          3. On a stable (at least 3 months) antiretroviral therapy with DTG 50 mg QD plus one RTI

          4. HIV-RNA &lt;50 copies/mL since at least 6 months

        Exclusion Criteria:

          1. Active AIDS-defining condition (except Kaposi's sarcoma non requiring systemic
             chemotherapy)

          2. Serious illness requiring systemic treatment and/or hospitalization

          3. Current use of immunomodulant or immunosuppressive drugs

          4. Need (or will likely need) of treatment with antacids

          5. Use of drugs contraindicated with study drugs, according to technical sheets

          6. Previous suboptimal therapies with NRTIs or presence of TAMs (type 1 or 2) in previous
             resistance tests (patients with the 184I/V mutation alone are allowed to enter the
             study)

          7. Resistance or previous virological failure to InSTIs

          8. Detectable HCV-RNA

          9. Documented allergy to COBI or EVG or FTC or tenofovir.

         10. Absolute neutrophil count (ANC) &lt;500/µL

         11. Haemoglobin &lt;8.0 g/dL

         12. Platelet count &lt;50,000/µL

         13. eGFR &lt;30 mL/min/1.73m2 by CKD-EPI equation

         14. Alanine aminotransferase (ALT) more than 5 times the upper limit of normal (ULN)

         15. Presence of Child Pugh Class B or C liver cirrhosis.

         16. Pregnancy or breastfeeding

         17. Woman of childbearing potential who does not agree to adopt highly effective
             contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriano Lazzarin, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale San Raffaele</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ADRIANO LAZZARIN, Prof</last_name>
    <phone>0226437939</phone>
    <email>lazzarin.adriano@hsr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antonella Castagna, Prof</last_name>
    <phone>0226437934</phone>
    <email>castagna.antonella1@hsr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <state>Lombardia</state>
        <zip>20127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ADRIANO LAZZARIN</last_name>
      <phone>0226437939</phone>
      <email>lazzarin.adriano@hsr.it</email>
    </contact>
    <contact_backup>
      <last_name>Elisabetta Carini</last_name>
      <phone>0226437934</phone>
      <email>carini.elisabetta@hsr.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele Scientific Institute</name>
      <address>
        <city>Milan</city>
        <zip>20127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Margolis DA, Brinson CC, Smith GHR, de Vente J, Hagins DP, Eron JJ, Griffith SK, Clair MHS, Stevens MC, Williams PE, Ford SL, Stancil BS, Bomar MM, Hudson KJ, Smith KY, Spreen WR; LAI116482 Study Team. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis. 2015 Oct;15(10):1145-1155. doi: 10.1016/S1473-3099(15)00152-8. Epub 2015 Jul 19.</citation>
    <PMID>26201299</PMID>
  </reference>
  <reference>
    <citation>Riddler SA, Aga E, Bosch RJ, Bastow B, Bedison M, Vagratian D, Vaida F, Eron JJ, Gandhi RT, Mellors JW; ACTG A5276s Protocol Team. Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy. J Infect Dis. 2016 Feb 15;213(4):556-60. doi: 10.1093/infdis/jiv433. Epub 2015 Sep 2.</citation>
    <PMID>26333941</PMID>
  </reference>
  <reference>
    <citation>Gianotti N, Canducci F, Galli L, Cossarini F, Salpietro S, Poli A, Nozza S, Spagnuolo V, Clementi M, Sampaolo M, Ceresola ER, Racca S, Lazzarin A, Castagna A. HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients. Clin Microbiol Infect. 2015 Jan;21(1):103.e7-103.e10. doi: 10.1016/j.cmi.2014.08.004. Epub 2014 Oct 13.</citation>
    <PMID>25636935</PMID>
  </reference>
  <reference>
    <citation>Gianotti N, Galli L, Salpietro S, Cernuschi M, Bossolasco S, Maillard M, Spagnuolo V, Canducci F, Clementi M, Lazzarin A, Castagna A. Virological rebound in human immunodeficiency virus-infected patients with or without residual viraemia: results from an extended follow-up. Clin Microbiol Infect. 2013 Dec;19(12):E542-4. doi: 10.1111/1469-0691.12266. Epub 2013 Jul 24.</citation>
    <PMID>23890370</PMID>
  </reference>
  <reference>
    <citation>Maggiolo F, Callegaro A, Cologni G, Bernardini C, Velenti D, Gregis G, Quinzan G, Soavi L, Iannotti N, Malfatto E, Leone S. Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. J Acquir Immune Defic Syndr. 2012 Aug 15;60(5):473-82. doi: 10.1097/QAI.0b013e3182567a57.</citation>
    <PMID>22481602</PMID>
  </reference>
  <reference>
    <citation>Doyle T, Smith C, Vitiello P, Cambiano V, Johnson M, Owen A, Phillips AN, Geretti AM. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2012 Mar 1;54(5):724-32. doi: 10.1093/cid/cir936. Epub 2012 Jan 11.</citation>
    <PMID>22238167</PMID>
  </reference>
  <reference>
    <citation>Mills A, Arribas JR, Andrade-Villanueva J, DiPerri G, Van Lunzen J, Koenig E, Elion R, Cavassini M, Madruga JV, Brunetta J, Shamblaw D, DeJesus E, Orkin C, Wohl DA, Brar I, Stephens JL, Girard PM, Huhn G, Plummer A, Liu YP, Cheng AK, McCallister S; GS-US-292-0109 team. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016 Jan;16(1):43-52. doi: 10.1016/S1473-3099(15)00348-5. Epub 2015 Nov 2.</citation>
    <PMID>26538525</PMID>
  </reference>
  <reference>
    <citation>Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, Dewar RL, Planta A, Liu S, Metcalf JA, Mellors JW, Coffin JM. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2003 Oct;41(10):4531-6.</citation>
    <PMID>14532178</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2018</study_first_submitted>
  <study_first_submitted_qc>April 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2018</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale San Raffaele</investigator_affiliation>
    <investigator_full_name>Castagna Antonella</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dolutegravir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Cobicistat</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data shared in Scientific Congress (abstract and pubblications)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

